Zevra Therapeutics (ZVRA) Income from Continuing Operations (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Income from Continuing Operations came in at 37890000.0 in Q1 2026, up 1322.65% YoY from 2663334.92 in Q1 2025, and up 211.47% on a QoQ basis from 12165000.0 in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Income from Continuing Operations data on file, last reported at 37890000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 1322.65% year-over-year to 37890000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124218000.0 (up 235.04% YoY) and the FY2025 annual result came in at 83229000.0, up 178.88% from the prior year.
- Income from Continuing Operations rose to 37890000.0 in Q1 2026, from 12165000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 74707000.0 in Q2 2025 to a low of 35739000.0 in Q4 2024.
- A 5-year average of 2976294.12 and a median of 5700000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 674.39% — and 2026, when it jumped 1322.65%.
- Tracing ZVRA's Income from Continuing Operations over 5 years: stood at 2972000.0 in 2022, then plunged by 569.31% to 19892000.0 in 2023, then slumped by 79.67% to 35739000.0 in 2024, then soared by 134.04% to 12165000.0 in 2025, then jumped by 211.47% to 37890000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 37890000.0 (Q1 2026), 12165000.0 (Q4 2025), and 544000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zevra Therapeutics | 735.30 Mn | 513.73 Mn | 38.18 Mn | 8.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.75 Mn |
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.37 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -13.22 Mn |
| Dec 31, 2022 | 5.75 Mn |
| Sep 30, 2022 | -6.62 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Mar 31, 2022 | -1.86 Mn |
| Dec 31, 2021 | -2.70 Mn |
| Sep 30, 2021 | -1.76 Mn |